On Friday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was -9.98% drop from the session before settling in for the closing price of $5.91. A 52-week range for RXRX has been $3.79 – $12.36.
Annual sales at Healthcare sector company slipped by -35.28% over the past five years. When this article was written, the company’s average yearly earnings per share was at 6.66%. With a float of $332.98 million, this company’s outstanding shares have now reached $425.48 million.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Recursion Pharmaceuticals Inc stocks. The insider ownership of Recursion Pharmaceuticals Inc is 23.39%, while institutional ownership is 53.78%. The most recent insider transaction that took place on Oct 10 ’25, was worth 604,000. In this transaction Chief Executive Officer of this company sold 100,000 shares at a rate of $6.04, taking the stock ownership to the 974,229 shares. Before that another transaction happened on Oct 10 ’25, when Company’s Officer proposed sale 100,000 for $6.04, making the entire transaction worth $604,000.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.34 earnings per share (EPS) during the time that was less than consensus figure (set at -0.33) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.35% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
You can see what Recursion Pharmaceuticals Inc (RXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.28 in one year’s time.
